Best of ASCO - 2014 Annual Meeting



Kidney Cancer

Genitourinary (Nonprostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
A FARETES study of the efficacy and safety of testosterone in metastatic renal cell carcinoma patients with fatigue.

Ilya Tsimafeyeu


A meta-analysis of randomized controlled trials for efficacy and safety of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) adjuvant therapy in high-risk renal cell cancer (RCC).

Irbaz Bin Riaz


A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.

Ulka N. Vaishampayan


A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).

Axel Bex


A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Toni K. Choueiri


A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

Jianjun Gao


A randomized phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial).

Amado J. Zurita


A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.

Giuseppe Procopio


Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.

Philipp Ivanyi


Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.

Dominick Bossé


Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.

Dena Battle


Assessing DCE-MRI and DWI as treatment response biomarkers after SABR for primary renal cell carcinoma.

Hayley M Reynolds


Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC).

Nazli Dizman


Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC).

Eddy Shih-Hsin Yang


CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).

Guillermo de Velasco


Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.

Nieves Martinez Chanza


Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.

Alfonso Gomez de Liano


CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Nizar M. Tannir


Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.

Gennady Bratslavsky


CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

Arnaud Mejean


Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis.

Martin Henner Voss


Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.

Olumide B. Gbolahan


Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.

Pavlos Msaouel


Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma.

Keith Betts


Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

Eric Jonasch


Comparison of prognostic models for selecting synchronous mRCC patients who would benefit from upfront cytoreductive nephrectomy followedtargeted therapy.

Wei Zheng


Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

Jesús GarcÃa-Donas


Constitutive activation of mTOR pathways in renal cell carcinoma arising in dialyzed patients.

Ryuichi Mizuno


Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).

Martin Henner Voss


Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.

Alain Ravaud


Early assessment by FDG PET/CT to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.

Noboru Nakaigawa


Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Martin Boegemann


Efficacy and safety of endoscopic radiofrequency ablation for metastatic pancreatic renal cell carcinoma: A monocentric experience.

Gwenaelle Gravis


Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.

Xinan Sheng


Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal-cell carcinoma (RCC): Systematic review and meta-analysis.

Tobias Engel Ayer Botrel


Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Shubham Pant


Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC).

Patrick Glen Pilie


Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.

Lisa Derosa


High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience.

Shien Chow


Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC).

Annalisa Guida


Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).

Òscar Reig


Impact of adrenergic and prostanoid inhibitors used chronobiologically on outcomes in patients with metastatic renal cell carcinoma.

Gouri Shankar Bhattacharyya


Impact of disease progression on patient reported outcomes, hospitalization, and death in patients with stage IV, renal cell carcinoma.

Junji Lin


Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

Robert A. Figlin


KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

Toni K. Choueiri


Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.

Chung-Han Lee


Lenvatinib in combination with everolimus in metastatic renal cell carcinoma (mRCC) resistant to antiangiogenic targeted therapy: An initial Russian experience.

Maria Volkova


Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT).

Jose F. Corona-Cruz


Minimally invasive image guided thermal ablation for recurrent renal cell carcinoma (RCC) after ipsilateral partial nephrectomy.

Tessa N. Hudspeth


Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.

Anup Patel


NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).

Cristina Masini


Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.

Jad Chahoud


Novel oral nano-amorphous sirolimus formulation to exhibit comparable exposure to intravenously administered temsirolimus: An oral alternative to the treatment of mTOR-responsive malignancies.

Hristos Glavinas


Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.

Xiao X. Wei


Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study.

Jeremy Aaron Ross


Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.

Mayer N. Fishman


Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey.

Cristiane Decat Bergerot


Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

Bernard Escudier


Patterns of relapse and implications for post-nephrectomy surveillance for patients with high-risk non-clear cell renal cell carcinoma: Subgroup analysis of the phase 3 ECOG-ACRIN E2805 trial.

Vivek Narayan


Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Nizar M. Tannir


Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

David F. McDermott


Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1: A comparative study of clinical results for patients aged between less than 65 years and 65 years and older.

Zhigang Cheng


PET/CT assessment of tumor perfusion (TP) in metastatic renal cell cancer (RCC) patients (pts) on sunitinib (S) using 62Cu-ETS.

Theodore F. Logan


Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.

Arkadiusz Z. Dudek


Pilot trial of ibrutinib plus nivolumab in patients with metastatic renal cell cancer (mRCC): results from a dose-finding cohort.

Primo Lara


Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo).

Haris Zahoor


Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors.

Moshe Chaim Ornstein


Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL Study).

Manuela Schmidinger


PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

Lauren Christine Harshman


Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

Ronald C. Chen


Radiofrequency ablation of pathologically proven T1a renal tumors: 15 years follow up—A tertiary cancer center experience.

Mohamed E. Abdelsalam


Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.

Saskia Lisa Verhaart


Real world experience with nivolumab in Indian patients with metastatic renal cell carcinoma: A single centre experience.

Amit Rauthan


Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC).

Patrick Glen Pilie


Risk of health-related quality of life and metabolic events and pulmonary toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Rachana Yendala


Risk of hematological, gastrointestinal, and hepatic toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Henry Palangdao Igid


Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.

Leonard Joseph Appleman


Selection for active surveillance in mRCC by the CLEAR multigene score.

Ravindran Kanesvaran


Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.

Yasser Ged


Survival outcomes in sarcomatoid renal cell carcinoma.

Taha Al-Juhaishi


The clinical impact of serum C-reactive protein levels in metastatic renal-cell carcinoma patients treated by second-line molecular targeted therapies.

Kimiharu Takamatsu


Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma.

Viola Chen


Treatment patterns and effectiveness outcomes in patients with stage IV, renal cell carcinoma.

Ronda Copher


Using real-world data to develop clinical trial referral networks for metastatic renal cell carcinoma (mRCC).

Nobumasa Kawasaki


Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.

Jun Guo